Clearmind Medicine Inc Common Shares

Yahoo Finance • 5 days ago

Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies

Vancouver, Canada, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived... Full story

Yahoo Finance • 11 days ago

Clearmind Medicine registers 17M shares for resale linked to $10M convertible note deal

* Clearmind Medicine (NASDAQ:CMND [https://seekingalpha.com/symbol/CMND]) filed a prospectus to register the resale of up to 17.02M common shares by selling shareholders. * This includes: 16.97M shares tied to conversion of $2.5M in in... Full story

Yahoo Finance • 11 days ago

Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities

Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived... Full story

Yahoo Finance • 2 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases o... Full story

Yahoo Finance • 2 months ago

Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived t... Full story

Yahoo Finance • 2 months ago

Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

IRB Approval from Hadassah Medical Center Follows FDA IND Clearance and Prior Approvals from Additional Clinical Sites Vancouver, Canada, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind... Full story

Yahoo Finance • 2 months ago

Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived t... Full story

Yahoo Finance • 2 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases... Full story

Yahoo Finance • 2 months ago

Clearmind advances AUD treatment with new trial site in Tel Aviv

VANCOUVER - Clearmind Medicine Inc. (Nasdaq:CMND), a micro-cap biotech company valued at $5.8 million, announced Wednesday the completion of site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial eva... Full story

Yahoo Finance • 2 months ago

Clearmind Medicine Completes Initiation of Leading Israeli Clinical Site for Phase I/IIa Trial of CMND-100 in Alcohol Use Disorder

Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived... Full story

Yahoo Finance • 3 months ago

Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled

Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived... Full story

Yahoo Finance • 3 months ago

Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck

Company Logo The global alcohol use disorder market is experiencing significant growth, driven by increasing demand for innovative and personalized treatments, and the integration of digital health technologies. Advancements in pharmacoth... Full story

Yahoo Finance • 3 months ago

Sector Update: Health Care Stocks Mixed Thursday Afternoon

Health care stocks were mixed Thursday afternoon, with the NYSE Health Care Index down 0.1% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 3 months ago

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived... Full story

Yahoo Finance • 3 months ago

Clearmind doses first participant in alcohol disorder treatment trial

VANCOUVER - Clearmind Medicine Inc. (NASDAQ:CMND), a micro-cap biotech company with a market capitalization of $4.56 million, has dosed the first participant with its MEAI-based oral drug candidate CMND-100 in a Phase I/IIa clinical trial... Full story

Yahoo Finance • 3 months ago

Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived... Full story

Yahoo Finance • 3 months ago

Clearmind adds Hadassah Medical Center to alcohol disorder drug trial

VANCOUVER - Clearmind Medicine Inc. (NASDAQ:CMND), a micro-cap biotech company with a market capitalization of $4.53 million, has added Hadassah-University Medical Center in Jerusalem as a new clinical site for its ongoing Phase I/IIa tria... Full story

Yahoo Finance • 3 months ago

Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived... Full story

Yahoo Finance • 3 months ago

Clearmind enrolls first patient in CMND-100 alcohol disorder trial

NEW YORK - Clearmind Medicine Inc. (NASDAQ:CMND), a micro-cap biotech company with a market capitalization of $4.6 million and a current stock price of $0.90, has enrolled the first patient in its Phase I/IIa clinical trial for CMND-100, t... Full story

Yahoo Finance • 3 months ago

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Me... Full story